CRISPR Therapeutics AG — News

CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.

seekingalpha.com - 2026-08-05 10:09:04

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.

zacks.com - 2026-08-04 12:00:48

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago.

zacks.com - 2026-08-03 19:46:21

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.

globenewswire.com - 2026-08-03 16:15:00

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.

zacks.com - 2026-07-30 18:50:17

CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon.

fool.com - 2026-07-30 17:38:00

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

fool.com - 2026-07-30 16:30:00

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-07-28 10:01:24

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-27 11:03:18

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.08% shift from the previous trading day.

zacks.com - 2026-07-24 18:51:08

Ark Investment Management's high-profile stock picker Cathie Wood has bought stakes in CRISPR Therapeutics for a couple of the firm's funds. While it's typically considered a gene-editing play (and even named after the underlying genomic science), that's not all this biotechnology outfit is working on.

fool.com - 2026-07-22 05:30:00

Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,853,875 shares of the company's stock after selling 104,236 shares during the quarter. CRISPR

defenseworld.net - 2026-07-21 03:14:05

CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are imminent. CASGEVY's efficacy and expanding market access, combined with a robust cash position, underpin a favorable risk/reward at current levels.

seekingalpha.com - 2026-07-21 02:02:08

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

zacks.com - 2026-07-20 11:51:04

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.

zacks.com - 2026-07-17 18:51:11

CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.

zacks.com - 2026-07-16 19:01:10

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-07-14 10:01:21

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.

zacks.com - 2026-07-10 18:51:09

CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.

fool.com - 2026-07-10 13:00:00

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

fool.com - 2026-07-08 05:45:00

CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.

zacks.com - 2026-07-07 19:01:18

CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.

fool.com - 2026-07-07 13:45:00

Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.

schaeffersresearch.com - 2026-07-07 13:05:50

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.

fool.com - 2026-07-07 10:36:52

CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.

fool.com - 2026-07-06 07:35:01

CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.

fxempire.com - 2026-07-03 17:05:13

Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.

seekingalpha.com - 2026-07-03 12:14:32

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

fool.com - 2026-07-03 08:37:20

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com - 2026-06-30 10:01:40

CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.

fool.com - 2026-06-27 06:00:03

CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move from the prior day.

zacks.com - 2026-06-26 18:50:22

Exploring some of the top bargains in a multi-trillion-dollar industry.

fool.com - 2026-06-22 08:45:00

The opportunity is enormous, but uncertainty remains.

fool.com - 2026-06-18 09:00:00

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $53.09, indicating a +2.06% shift from the previous trading day.

zacks.com - 2026-06-17 18:50:30

They have at least one thing in common: An exciting pipeline.

fool.com - 2026-06-17 16:00:00

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

My strategy involves focusing on dividends, growth, and also taking on some calculated risk.

fool.com - 2026-06-17 12:30:00

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-06-16 10:01:19

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.

zacks.com - 2026-06-11 18:51:14

VO is a low-cost ETF offered by Vanguard, providing broad exposure to U.S. mid-cap stocks as defined by CRSP. However, CRSP Indexes allow overlap with the small/large-cap segments, impacting efficiency. As is common for Vanguard ETFs, VO will most likely deliver average category returns year to year, as it has done historically. However, it's not ideal from a fundamentals perspective. This article suggests combining XMHQ and XMMO to create a high-quality portfolio with strong momentum characteristics, potentially allowing for lesser drawdowns and faster recoveries.

seekingalpha.com - 2026-06-11 16:14:52

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.

zacks.com - 2026-06-10 19:01:56

CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 17:02:12

The biotech has won approval for one of the few gene-editing therapies on the market. Several more therapies based on the same science are in the works.

fool.com - 2026-06-08 12:53:00

CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript

seekingalpha.com - 2026-06-04 19:32:53

CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 21:32:00

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-03 12:30:37

CRISPR's Casgevy cements the company as a leader in gene-editing therapies. The company's commercial momentum should build as Casgevy reaches more patients.

fool.com - 2026-06-03 12:30:00

Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene editing-focused biotech.

fool.com - 2026-06-03 03:00:00

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

zacks.com - 2026-06-02 13:10:18

This little-discussed pipeline program could prove to be a big success.

fool.com - 2026-06-01 12:30:00